MRKR PE Ratio & Valuation,Is MRKR Overvalued

MRKR Relative Valuation

MRKR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MRKR is overvalued; if below, it's undervalued.

Historical Valuation

Marker Therapeutics Inc (MRKR) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.90. The fair price of Marker Therapeutics Inc (MRKR) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：1.39

Fair

-1.46

-0.39

EV/EBITDA

Marker Therapeutics Inc. (MRKR) has a current EV/EBITDA of -0.39. The 5-year average EV/EBITDA is -0.02. The thresholds are as follows: Strongly Undervalued below -0.29, Undervalued between -0.29 and -0.15, Fairly Valued between 0.12 and -0.15, Overvalued between 0.12 and 0.26, and Strongly Overvalued above 0.26. The current Forward EV/EBITDA of -0.39 falls within the Strongly Undervalued range.

-0.38

EV/EBIT

Marker Therapeutics Inc. (MRKR) has a current EV/EBIT of -0.38. The 5-year average EV/EBIT is -0.97. The thresholds are as follows: Strongly Undervalued below -3.54, Undervalued between -3.54 and -2.25, Fairly Valued between 0.32 and -2.25, Overvalued between 0.32 and 1.60, and Strongly Overvalued above 1.60. The current Forward EV/EBIT of -0.38 falls within the Historic Trend Line -Fairly Valued range.

9.87

Marker Therapeutics Inc. (MRKR) has a current PS of 9.87. The 5-year average PS is 6.81. The thresholds are as follows: Strongly Undervalued below -14.05, Undervalued between -14.05 and -3.62, Fairly Valued between 17.24 and -3.62, Overvalued between 17.24 and 27.67, and Strongly Overvalued above 27.67. The current Forward PS of 9.87 falls within the Historic Trend Line -Fairly Valued range.

-2.21

P/OCF

Marker Therapeutics Inc. (MRKR) has a current P/OCF of -2.21. The 5-year average P/OCF is -0.58. The thresholds are as follows: Strongly Undervalued below -2.32, Undervalued between -2.32 and -1.45, Fairly Valued between 0.29 and -1.45, Overvalued between 0.29 and 1.16, and Strongly Overvalued above 1.16. The current Forward P/OCF of -2.21 falls within the Undervalued range.

-2.38

P/FCF

Marker Therapeutics Inc. (MRKR) has a current P/FCF of -2.38. The 5-year average P/FCF is -1.55. The thresholds are as follows: Strongly Undervalued below -5.19, Undervalued between -5.19 and -3.37, Fairly Valued between 0.28 and -3.37, Overvalued between 0.28 and 2.10, and Strongly Overvalued above 2.10. The current Forward P/FCF of -2.38 falls within the Historic Trend Line -Fairly Valued range.

Marker Therapeutics Inc (MRKR) has a current Price-to-Book (P/B) ratio of 1.27. Compared to its 3-year average P/B ratio of 2.11 , the current P/B ratio is approximately -39.79% higher. Relative to its 5-year average P/B ratio of 2.09, the current P/B ratio is about -39.25% higher. Marker Therapeutics Inc (MRKR) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -74.62%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -67.70% , the current FCF yield is about -100.00% lower.

1.27

P/B

Median3y

2.11

Median5y

2.09

-60.45

FCF Yield

Median3y

-74.62

Median5y

-67.70

Competitors Valuation Multiple

The average P/S ratio for MRKR's competitors is 0.00, providing a benchmark for relative valuation. Marker Therapeutics Inc Corp (MRKR) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -35.99%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of MRKR decreased by 55.31% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -119.84 to -162.11.

The secondary factor is the Revenue Growth, contributed -35.99%to the performance.

Overall, the performance of MRKR in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-35.99%

1.93M → 1.23M

Revenue Growth

35.27%

-119.84 → -162.11

Margin Expansion

-54.59%

-2.75 → -1.25

P/E Change

-55.31%

3.11 → 1.39

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Marker Therapeutics Inc (MRKR) currently overvalued or undervalued?

What is Marker Therapeutics Inc (MRKR) fair value?

MRKR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Marker Therapeutics Inc (MRKR) is between NaN to NaN according to relative valuation methord.

How does MRKR's valuation metrics compare to the industry average?

What is the current P/B ratio for Marker Therapeutics Inc (MRKR) as of Dec 16 2025?

As of Dec 16 2025, Marker Therapeutics Inc (MRKR) has a P/B ratio of 1.27. This indicates that the market values MRKR at 1.27 times its book value.

What is the current FCF Yield for Marker Therapeutics Inc (MRKR) as of Dec 16 2025?

As of Dec 16 2025, Marker Therapeutics Inc (MRKR) has a FCF Yield of 0.00%. This means that for every dollar of Marker Therapeutics Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Marker Therapeutics Inc (MRKR) as of Dec 16 2025?

As of Dec 16 2025, Marker Therapeutics Inc (MRKR) has a Forward P/E ratio of -1.46. This means the market is willing to pay $-1.46 for every dollar of Marker Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Marker Therapeutics Inc (MRKR) as of Dec 16 2025?

As of Dec 16 2025, Marker Therapeutics Inc (MRKR) has a Forward P/S ratio of 0.00. This means the market is valuing MRKR at $0.00 for every dollar of expected revenue over the next 12 months.

MRKR Valuation